Megan Prunty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Megan Prunty has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Laura Bukavina
Department of Urology, Integrated Surgical Institute, Cleveland Clinic, Cleveland, USA
42 shared publications - Lee Ponsky
Department of Urology, Case Western Reserve University, Cleveland, Ohio
42 shared publications - Adam Calaway
Department of Urology, Case Western Reserve University, Cleveland, Ohio
41 shared publications - Kirtishri Mishra
Case Western Reserve School of Medicine, Cleveland, OH, USA; University Hospitals Cleveland Medical Center, Cleveland, OH, USA
41 shared publications - Alexander Kutikov
Fox Chase Cancer Center, Philadelphia, USA
40 shared publications - Mohit Sindhani
India Institute of Technology, Delhi, India
40 shared publications
Latest Publications
- Open Access
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Microbial composition variance in relation to chemotherapy response in patients with bladder cancer. A, Proportional representation of the GM's phylogenetic composition in patients showing CR versus NR to NAC (Also depicted in C). B, Alpha diversity metrics compared across response groups, highlighting minimal statistical disparities. D, Weighted UniFrac PCoA depicting the lack of distinct microbial clustering by response category. E–G, Venn diagram and LEfSe analysis illustrating unique and differentially abundant microbial taxa associated with NAC responses, enriched in either CR or NR groups, along with a taxonomic cladogram delineating these associations.
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Microbial composition variance in relation to chemotherapy response in patients with bladder cancer. A, Proportional representation of the GM's phylogenetic composition in patients showing CR versus NR to NAC (Also depicted in C). B, Alpha diversity metrics compared across response groups, highlighting minimal statistical disparities. D, Weighted UniFrac PCoA depicting the lack of distinct microbial clustering by response category. E–G, Venn diagram and LEfSe analysis illustrating unique and differentially abundant microbial taxa associated with NAC responses, enriched in either CR or NR groups, along with a taxonomic cladogram delineating these associations.
- Open Access
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Supplementary Figure 2: Patient Recruitment Flow Chart Flowchart illustrating the step-by-step recruitment process of bladder cancer patients, detailing inclusion and exclusion criteria and subsequent enrollment stages
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Supplementary Figure 2: Patient Recruitment Flow Chart Flowchart illustrating the step-by-step recruitment process of bladder cancer patients, detailing inclusion and exclusion criteria and subsequent enrollment stages
- Open Access
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Supplementary Figure 6: Gut Microbiome Dynamics During Neoadjuvant ChemotherapyA: Relative abundance of major bacterial genera before, during, and after chemotherapy. Each color represents a different genus, with patient-specific changes highlighted to illustrate shifts in microbial composition over the course of treatment.B: Violin plots representing alpha diversity indices (ACE, Chao1, Observed, Pielou, Shannon, and Simpson) at three stages of chemotherapy: before, during, and after treatment.C: Cladogram derived from LEfSe analysis illustrating the most significantly altered taxa at each treatment stage. Colored nodes indicate taxa with statistically significant differences in abundance, with arrows highlighting key changes before, during, and after chemotherapy.D: Each segment shows the percentage composition of each genus by treatment stage.E: Venn diagram summarizing the overlap and unique bacterial taxa found at each stage of chemotherapy, quantifying shared and exclusive genera before, during, and after treatment.F: Principal Coordinates Analysis (PCoA) plot based on weighted UniFrac distances, showing the clustering of microbial communities at different treatment stages.G: Bar graph illustrating the proportional changes in specific bacterial genera over the course of chemotherapy, quantified and compared across three phases.
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Supplementary Figure 6: Gut Microbiome Dynamics During Neoadjuvant ChemotherapyA: Relative abundance of major bacterial genera before, during, and after chemotherapy. Each color represents a different genus, with patient-specific changes highlighted to illustrate shifts in microbial composition over the course of treatment.B: Violin plots representing alpha diversity indices (ACE, Chao1, Observed, Pielou, Shannon, and Simpson) at three stages of chemotherapy: before, during, and after treatment.C: Cladogram derived from LEfSe analysis illustrating the most significantly altered taxa at each treatment stage. Colored nodes indicate taxa with statistically significant differences in abundance, with arrows highlighting key changes before, during, and after chemotherapy.D: Each segment shows the percentage composition of each genus by treatment stage.E: Venn diagram summarizing the overlap and unique bacterial taxa found at each stage of chemotherapy, quantifying shared and exclusive genera before, during, and after treatment.F: Principal Coordinates Analysis (PCoA) plot based on weighted UniFrac distances, showing the clustering of microbial communities at different treatment stages.G: Bar graph illustrating the proportional changes in specific bacterial genera over the course of chemotherapy, quantified and compared across three phases.
- Open Access
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Supplementary Figure 1: Overview of Sample Collection and Experimental Setup Diagram outlining the protocols for human fecal sample collection across various time points during chemotherapy in bladder cancer patients, accompanied by the setup of the murine bladder cancer model to study the gut microbiome.
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Supplementary Figure 1: Overview of Sample Collection and Experimental Setup Diagram outlining the protocols for human fecal sample collection across various time points during chemotherapy in bladder cancer patients, accompanied by the setup of the murine bladder cancer model to study the gut microbiome.
- Open Access
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Supplementary Data from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Supplementary Data from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
- Open Access
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Supplementary Figure 1: Overview of Sample Collection and Experimental Setup Diagram outlining the protocols for human fecal sample collection across various time points during chemotherapy in bladder cancer patients, accompanied by the setup of the murine bladder cancer model to study the gut microbiome.
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Supplementary Figure 1: Overview of Sample Collection and Experimental Setup Diagram outlining the protocols for human fecal sample collection across various time points during chemotherapy in bladder cancer patients, accompanied by the setup of the murine bladder cancer model to study the gut microbiome.
- Open Access
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Analysis of SCFA concentrations in relation to chemotherapy response. Top: Mean SCFA concentrations in plasma and stool of patients with bladder cancer categorized by NAC response status (CR vs. NR), showing no significant differences. Bottom: Correlation matrices between SCFA levels and bacterial genera in plasma and stool, with the strongest positive and negative correlations marked, indicating the metabolic interactions within the GM in the context of cancer therapy response.
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Analysis of SCFA concentrations in relation to chemotherapy response. Top: Mean SCFA concentrations in plasma and stool of patients with bladder cancer categorized by NAC response status (CR vs. NR), showing no significant differences. Bottom: Correlation matrices between SCFA levels and bacterial genera in plasma and stool, with the strongest positive and negative correlations marked, indicating the metabolic interactions within the GM in the context of cancer therapy response.
- Open Access
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 6 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Longitudinal microbiota analysis in a murine model exposed to BBN versus water. A, Shannon diversity index measures across different timepoints (0, 6, 12, 16–22 weeks) showing changes in alpha diversity in mice treated with BBN compared with those given water. Each point represents a time-specific diversity score, providing insights into the temporal dynamics of microbial diversity. B, PCoA plot of beta diversity based on Weighted UniFrac distances, illustrating the microbial community variations over time between BBN-treated and control groups. Significant differences are highlighted, demonstrating the impact of BBN exposure on microbial community structure. C, LDA scores quantifying the effect sizes of differentially abundant taxa between the BBN and water groups at each assessed timepoint. This visualization identifies specific taxa that are significantly impacted by BBN treatment. D, Bar graphs of the relative abundances of key bacterial taxa at different timepoints for BBN-treated versus water-treated mice. This detailed breakdown provides a clearer understanding of how specific bacterial populations fluctuate in response to carcinogen exposure. E, Relative abundance profiles of major bacterial genera across all timepoints, comparing BBN and water treatments. F, Fluctuation patterns of Bacteroides prevalence in the BBN and water groups, plotted across the study duration. G, Temporal trajectories of various bacterial OTUs between BBN and water groups, providing a longitudinal view of microbial changes and stability in response to treatment.
- 17 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 6 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
Longitudinal microbiota analysis in a murine model exposed to BBN versus water. A, Shannon diversity index measures across different timepoints (0, 6, 12, 16–22 weeks) showing changes in alpha diversity in mice treated with BBN compared with those given water. Each point represents a time-specific diversity score, providing insights into the temporal dynamics of microbial diversity. B, PCoA plot of beta diversity based on Weighted UniFrac distances, illustrating the microbial community variations over time between BBN-treated and control groups. Significant differences are highlighted, demonstrating the impact of BBN exposure on microbial community structure. C, LDA scores quantifying the effect sizes of differentially abundant taxa between the BBN and water groups at each assessed timepoint. This visualization identifies specific taxa that are significantly impacted by BBN treatment. D, Bar graphs of the relative abundances of key bacterial taxa at different timepoints for BBN-treated versus water-treated mice. This detailed breakdown provides a clearer understanding of how specific bacterial populations fluctuate in response to carcinogen exposure. E, Relative abundance profiles of major bacterial genera across all timepoints, comparing BBN and water treatments. F, Fluctuation patterns of Bacteroides prevalence in the BBN and water groups, plotted across the study duration. G, Temporal trajectories of various bacterial OTUs between BBN and water groups, providing a longitudinal view of microbial changes and stability in response to treatment.